EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression
EPHA3 promotes the malignant progression of gastrointestinal stromal tumors.
EPHA3 expression is elevated in high‑risk gastrointestinal stromal tumors (GISTs) and contributes to aggressive cellular behavior in vitro. Loss‑of‑function studies demonstrate that EPHA3 knockout attenuates proliferation and migration while promoting apoptosis, suggesting a role in malignant progression.
This finding identifies EPHA3 as a potential therapeutic target and biomarker in high‑risk GISTs, guiding future clinical interventions.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)